Scott R Goldsmith,Shawn Streeter,Fahrettin Covut
Scott R Goldsmith
Purpose of review: Advances in multiple myeloma therapies have greatly improved outcomes for patients living with the disease, although to date there is yet to be a cure. Cellular and immunotherapies, approved or in devel...
Anmol Baranwal,Christopher N Hahn,Mithun Vinod Shah et al.
Anmol Baranwal et al.
Purpose of review: Therapy-related myeloid neoplasms (t-MNs) are aggressive leukemias that develop following exposure to DNA-damaging agents. A subset of patients developing t-MN may have an inherited susceptibility to de...
Julian A Waksal,John Mascarenhas
Julian A Waksal
Purpose of review: To discuss the current treatment paradigm, review novel targets, and summarize completed and ongoing clinical trials that may lead to a paradigm shifts in the management of myelofibrosis (MF). ...
Shristi Upadhyay Banskota,Nabin Khanal,Rosalyn I Marar et al.
Shristi Upadhyay Banskota et al.
Purpose of review: We review how understanding the fitness and comorbidity burden of patients, and molecular landscape of underlying acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) at the time of diagnosis...
Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication [0.03%]
高危慢性髓系 leukemia的定义：风险评分、基因组景观及预后判断
Nur Hezrin Shahrin,Carol Wadham,Susan Branford
Nur Hezrin Shahrin
Purpose of review: The chronic myeloid leukemia (CML) treatment success story is incomplete as some patients still fail therapy, leading to end-stage disease and death. Here we discuss recent research into CML incidence, ...
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia [0.03%]
风险分层及真性红细胞增多症和原发性血小板增多症治疗进展
Ivan Krecak,Marko Lucijanic,Srdan Verstovsek
Ivan Krecak
Purpose of review: Estimating and modifying thrombotic risk is currently the mainstay of care for patients with polycythemia vera (PV) and essential thrombocythemia (ET). In recent years, however, increased attention has ...
Maegan Ford,Michael Mauro,Catherine Aftandilian et al.
Maegan Ford et al.
Purpose of review: Due to lack of pediatric-specific data, the management of chronic myeloid leukemia (CML) in pediatric, adolescents, and young adults is guided by adult CML evidence-based recommendations. Pediatric CML ...
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms [0.03%]
DDX41的胚系和体细胞缺陷及其对髓系肿瘤的影响
Talha Badar,Timothy Chlon
Talha Badar
Purpose of review: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history...
ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms [0.03%]
ANKRD26相关的血小板减少症和髓系肿瘤易感性
Mia J Sullivan,Elizabeth L Palmer,Juliana Perez Botero
Mia J Sullivan
Purpose of review: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and man...
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies [0.03%]
CHEK2和ATM种系变异与髓系及其他血液系统恶性肿瘤的关系
Ryan J Stubbins,Sophia Korotev,Lucy A Godley
Ryan J Stubbins
Purpose of review: An intact DNA damage response is crucial to preventing cancer development, including in myeloid and lymphoid malignancies. Deficiencies in the homologous recombination (HR) pathway can lead to defective...